These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 31396265)

  • 1. Increase in DNA Damage by MYCN Knockdown Through Regulating Nucleosome Organization and Chromatin State in Neuroblastoma.
    Hu X; Zheng W; Zhu Q; Gu L; Du Y; Han Z; Zhang X; Carter DR; Cheung BB; Qiu A; Jiang C
    Front Genet; 2019; 10():684. PubMed ID: 31396265
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bmi1 is a MYCN target gene that regulates tumorigenesis through repression of KIF1Bbeta and TSLC1 in neuroblastoma.
    Ochiai H; Takenobu H; Nakagawa A; Yamaguchi Y; Kimura M; Ohira M; Okimoto Y; Fujimura Y; Koseki H; Kohno Y; Nakagawara A; Kamijo T
    Oncogene; 2010 May; 29(18):2681-90. PubMed ID: 20190806
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MYCN-induced E2F5 promotes neuroblastoma cell proliferation through regulating cell cycle progression.
    Liu Y; Liu D; Wan W
    Biochem Biophys Res Commun; 2019 Mar; 511(1):35-40. PubMed ID: 30765227
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A genome-wide search for promoters that respond to increased MYCN reveals both new oncogenic and tumor suppressor microRNAs associated with aggressive neuroblastoma.
    Shohet JM; Ghosh R; Coarfa C; Ludwig A; Benham AL; Chen Z; Patterson DM; Barbieri E; Mestdagh P; Sikorski DN; Milosavljevic A; Kim ES; Gunaratne PH
    Cancer Res; 2011 Jun; 71(11):3841-51. PubMed ID: 21498633
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MYCN and PRC1 cooperatively repress docosahexaenoic acid synthesis in neuroblastoma via ELOVL2.
    Ding Y; Yang J; Ma Y; Yao T; Chen X; Ge S; Wang L; Fan X
    J Exp Clin Cancer Res; 2019 Dec; 38(1):498. PubMed ID: 31856871
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lysine-specific demethylase (LSD1/KDM1A) and MYCN cooperatively repress tumor suppressor genes in neuroblastoma.
    Amente S; Milazzo G; Sorrentino MC; Ambrosio S; Di Palo G; Lania L; Perini G; Majello B
    Oncotarget; 2015 Jun; 6(16):14572-83. PubMed ID: 26062444
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cellular retinoic acid-binding protein II is a direct transcriptional target of MycN in neuroblastoma.
    Gupta A; Williams BR; Hanash SM; Rawwas J
    Cancer Res; 2006 Aug; 66(16):8100-8. PubMed ID: 16912187
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MYCN acts as a direct co-regulator of p53 in MYCN amplified neuroblastoma.
    Agarwal S; Milazzo G; Rajapakshe K; Bernardi R; Chen Z; Barbieri E; Koster J; Perini G; Coarfa C; Shohet JM
    Oncotarget; 2018 Apr; 9(29):20323-20338. PubMed ID: 29755654
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Direct regulation of the minichromosome maintenance complex by MYCN in neuroblastoma.
    Koppen A; Ait-Aissa R; Koster J; van Sluis PG; Ora I; Caron HN; Volckmann R; Versteeg R; Valentijn LJ
    Eur J Cancer; 2007 Nov; 43(16):2413-22. PubMed ID: 17826980
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic targeting of the MYC signal by inhibition of histone chaperone FACT in neuroblastoma.
    Carter DR; Murray J; Cheung BB; Gamble L; Koach J; Tsang J; Sutton S; Kalla H; Syed S; Gifford AJ; Issaeva N; Biktasova A; Atmadibrata B; Sun Y; Sokolowski N; Ling D; Kim PY; Webber H; Clark A; Ruhle M; Liu B; Oberthuer A; Fischer M; Byrne J; Saletta F; Thwe le M; Purmal A; Haderski G; Burkhart C; Speleman F; De Preter K; Beckers A; Ziegler DS; Liu T; Gurova KV; Gudkov AV; Norris MD; Haber M; Marshall GM
    Sci Transl Med; 2015 Nov; 7(312):312ra176. PubMed ID: 26537256
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting MYCN-Driven Transcription By BET-Bromodomain Inhibition.
    Henssen A; Althoff K; Odersky A; Beckers A; Koche R; Speleman F; Schäfers S; Bell E; Nortmeyer M; Westermann F; De Preter K; Florin A; Heukamp L; Spruessel A; Astrahanseff K; Lindner S; Sadowski N; Schramm A; Astorgues-Xerri L; Riveiro ME; Eggert A; Cvitkovic E; Schulte JH
    Clin Cancer Res; 2016 May; 22(10):2470-81. PubMed ID: 26631615
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A SP1/MIZ1/MYCN repression complex recruits HDAC1 at the TRKA and p75NTR promoters and affects neuroblastoma malignancy by inhibiting the cell response to NGF.
    Iraci N; Diolaiti D; Papa A; Porro A; Valli E; Gherardi S; Herold S; Eilers M; Bernardoni R; Della Valle G; Perini G
    Cancer Res; 2011 Jan; 71(2):404-12. PubMed ID: 21123453
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chromatin remodeling during the in vivo glial differentiation in early Drosophila embryos.
    Ye Y; Gu L; Chen X; Shi J; Zhang X; Jiang C
    Sci Rep; 2016 Sep; 6():33422. PubMed ID: 27634414
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genome-Wide Mapping Targets of the Metazoan Chromatin Remodeling Factor NURF Reveals Nucleosome Remodeling at Enhancers, Core Promoters and Gene Insulators.
    Kwon SY; Grisan V; Jang B; Herbert J; Badenhorst P
    PLoS Genet; 2016 Apr; 12(4):e1005969. PubMed ID: 27046080
    [TBL] [Abstract][Full Text] [Related]  

  • 15. GRHL1 acts as tumor suppressor in neuroblastoma and is negatively regulated by MYCN and HDAC3.
    Fabian J; Lodrini M; Oehme I; Schier MC; Thole TM; Hielscher T; Kopp-Schneider A; Opitz L; Capper D; von Deimling A; Wiegand I; Milde T; Mahlknecht U; Westermann F; Popanda O; Roels F; Hero B; Berthold F; Fischer M; Kulozik AE; Witt O; Deubzer HE
    Cancer Res; 2014 May; 74(9):2604-16. PubMed ID: 24419085
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functionally distinct patterns of nucleosome remodeling at enhancers in glucocorticoid-treated acute lymphoblastic leukemia.
    Wu JN; Pinello L; Yissachar E; Wischhusen JW; Yuan GC; Roberts CWM
    Epigenetics Chromatin; 2015; 8():53. PubMed ID: 26633995
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MYCN promotes neuroblastoma malignancy by establishing a regulatory circuit with transcription factor AP4.
    Xue C; Yu DM; Gherardi S; Koach J; Milazzo G; Gamble L; Liu B; Valli E; Russell AJ; London WB; Liu T; Cheung BB; Marshall GM; Perini G; Haber M; Norris MD
    Oncotarget; 2016 Aug; 7(34):54937-54951. PubMed ID: 27448979
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alternative NHEJ pathway proteins as components of MYCN oncogenic activity in human neural crest stem cell differentiation: implications for neuroblastoma initiation.
    Newman EA; Chukkapalli S; Bashllari D; Thomas TT; Van Noord RA; Lawlor ER; Hoenerhoff MJ; Opipari AW; Opipari VP
    Cell Death Dis; 2017 Dec; 8(12):3208. PubMed ID: 29238067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nucleosome eviction along with H3K9ac deposition enhances Sox2 binding during human neuroectodermal commitment.
    Du Y; Liu Z; Cao X; Chen X; Chen Z; Zhang X; Zhang X; Jiang C
    Cell Death Differ; 2017 Jun; 24(6):1121-1131. PubMed ID: 28475175
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BPTF cooperates with MYCN and MYC to link neuroblastoma cell cycle control to epigenetic cellular states.
    Felipe I; Martínez-de-Villarreal J; Patel K; Martínez-Torrecuadrada J; Grossmann LD; Roncador G; Cubells M; Farrell A; Kendsersky N; Sabroso-Lasa S; Sancho-Temiño L; Torres K; Martinez D; Perez JM; García F; Pogoriler J; Moreno L; Maris JM; Real FX
    bioRxiv; 2024 Feb; ():. PubMed ID: 38405949
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.